Headline partners

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. With over 100 years of scientific heritage, we actively focus on developing innovative treatments for patients in five important therapeutic areas of healthcare: oncology, immunology, neuroscience, infectious diseases & vaccines and cardiovascular & metabolic diseases. Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with patient organisations, healthcare professionals and the NHS; based on partnerships of trust and transparency. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more about Janssen-Cilag Limited at: Follow us on Twitter: @JanssenUK.

Pfizer: Transforming UK health, one patient at a time

Pfizer is committed to supporting healthcare quality improvement initiatives and research. In 2016, Pfizer spent over £250 million supporting research and development carried out in the UK and contributed to 162 collaborations with universities, pharmaceutical companies, industries and others. Through such collaborations and sharing knowledge, skills and expertise, Pfizer aim to improve the health and lives of people in the UK and around the world.

Complementing Pfizer’s long-standing commitment to innovative research and development, Pfizer also supports healthcare organisations, academic institutions, charities, patient organisations, community organisations, and professional societies through donations. Pfizer also actively supports the scientists of tomorrow, through the National Apprenticeship Programme, its undergraduate placement scheme and through various STEM (Science Technology Engineering and Mathematics) and SIP (Science Industry Partnership) activities.


Sanofi: Life is a health journey

Each and every person in the UK faces health challenges which can be big, small, lifelong or momentary.  At Sanofi, our commitments to patients are the cornerstone of our daily activities.

We work with a diverse range of stakeholders; from clinicians, their patients and carers to policymakers, healthcare economists and administrators, voluntary and non-governmental organisations, patient advocacy associations and our own employees, suppliers, shareholders and business partners.

In the UK, we have invested in external R&D and clinical trials, and partner a strong and diverse range of universities and related institutions with established technology transfer groups.

In support of IMI – Innovation Medicines Initiative – from the European Union, we have developed over 60 innovation partnerships across the UK, with more than 160 academic participants over 20 areas.

Our partnership strategy, particularly in biotechnologies and biotherapy, forges strategic collaborations with recognised experts around the world to achieve faster, better progress towards new therapeutic solutions.

At every level, Sanofi is committed to turning external scientific breakthroughs into successful innovative products.




Supporting partners

This activity has been supported by grants from the following companies. They have had no control over the educational content of this activity.

  • Celgene

  • Roche Products Limited